These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31875779)

  • 1. Prognostic Utility of Troponin I and N Terminal-ProBNP among Patients with Heart Failure due to Non-Ischemic Cardiomyopathy and Important Correlations.
    Mene-Afejuku TO; Dumancas C; Akinlonu A; Ola O; Cativo EH; Veranyan S; Lopez PD; Kim KS; Pekler G; Mushiyev S; Visco F
    Cardiovasc Hematol Agents Med Chem; 2019; 17(2):94-103. PubMed ID: 31875779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
    Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
    Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
    Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
    Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
    Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
    Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
    Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic utility of combination of NT-proBNP with high sensitive cTn I in patients with heart failure: Results from retrospective study in an emergency department.
    Cheng H; Fan WZ; Wang SC; Geng J; Zang HL; Shen XH; Liu ZH; Wang LZ
    Scand J Clin Lab Invest; 2016 Sep; 76(5):361-7. PubMed ID: 27228479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
    Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
    Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NT-ProBNP and hsTnI: A Multistate Survival Analysis in Outpatients with Reduced Left-Ventricular Ejection Fraction.
    Di Gesaro G; Caccamo G; Bellavia D; Falletta C; Minà C; Romano G; Agnese V; Tuzzolino F; Clemenza F
    Cardiology; 2019; 142(1):7-13. PubMed ID: 30852580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Heart fatty acid binding protein in patients hospitalized because of worsening heart failure. Relation to prognosis of death].
    Mazovets OL; Trifonov IR; Katrukha AG; Bereznikova AV; Medvedeva MV; Deev AD; Gratsianksiĭ NA
    Kardiologiia; 2008; 48(1):24-9. PubMed ID: 18260992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
    Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
    Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.
    Emdin M; Aimo A; Vergaro G; Bayes-Genis A; Lupón J; Latini R; Meessen J; Anand IS; Cohn JN; Gravning J; Gullestad L; Broch K; Ueland T; Nymo SH; Brunner-La Rocca HP; de Boer RA; Gaggin HK; Ripoli A; Passino C; Januzzi JL
    J Am Coll Cardiol; 2018 Nov; 72(19):2309-2320. PubMed ID: 30384887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
    Faxén UL; Lund LH; Orsini N; Strömberg A; Andersson DC; Linde C; Dahlström U; Savarese G
    Int J Cardiol; 2019 Jul; 287():66-72. PubMed ID: 31005415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
    Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
    Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV
    JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Admission and predischarge levels of NT pre brain natriuretic peptide in patients hospitalized because of worsening heart failure. relation to risk of death in the next 6-12 months].
    Mazovets OL; Trifonov IR; Katrukha AG; Gratsianskiĭ NA
    Kardiologiia; 2009; 49(1):34-8. PubMed ID: 19166399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.